Catalyst Pharmaceuticals Inc (CPRX)

0.74
0.00 0.28
NASDAQ : Health Care
Prev Close 0.74
Open 0.74
Day Low/High 0.72 / 0.76
52 Wk Low/High 0.51 / 5.46
Volume 220.85K
Avg Volume 886.30K
Exchange NASDAQ
Shares Outstanding 82.87M
Market Cap 62.15M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Catalyst Pharmaceuticals Announces First Quarter 2016 Financial Results And Provides Corporate Update

Catalyst Pharmaceuticals Announces First Quarter 2016 Financial Results And Provides Corporate Update

Company to Host Quarterly Conference Call at 8:30 am EDT Tomorrow

Anavex Plays the Orphan Drug Stock Promotion Game

Anavex Plays the Orphan Drug Stock Promotion Game

Too many investors have a fundamental misunderstanding about the significance of orphan drug designation. I should say, insignificance, because the FDA delineation, on its own, means very little.

Catalyst Pharmaceuticals Announces Fourth Quarter And Year-End 2015 Financial Results

Catalyst Pharmaceuticals Announces Fourth Quarter And Year-End 2015 Financial Results

Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow

Catalyst Pharmaceuticals (CPRX) Stock Plunges After FDA 'Refusal to File' Letter

Catalyst Pharmaceuticals (CPRX) Stock Plunges After FDA 'Refusal to File' Letter

Catalyst Pharmaceuticals (CPRX) stock is sinking on heavy trading volume on Wednesday after the company announced that it received a 'Refusal to File' letter from the FDA.

Catalyst Pharma Plummets on FDA 'Refuse-to-File' Letter

Catalyst Pharma Plummets on FDA 'Refuse-to-File' Letter

The FDA deems the approval application for the Catalyst drug Firdapse to be 'not sufficiently complete' and requests additional information.

Interesting CPRX Call Options For September 16th

Interesting CPRX Call Options For September 16th

Investors in Catalyst Pharmaceuticals Inc saw new options begin trading this week, for the September 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Catalyst Pharmaceuticals Announces Third Quarter 2015 Financial Results And Provides Corporate Update

Catalyst Pharmaceuticals Announces Third Quarter 2015 Financial Results And Provides Corporate Update

Company to host quarterly conference call at 8:30am ET tomorrow

CPRX: Insiders vs. Shorts

CPRX: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 09/30/2015 settlement date, and Catalyst Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 8.73 "days to cover" versus the median component at 5.50. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Doctors, Patients Battling Sky-High Drug Price Increase

Doctors, Patients Battling Sky-High Drug Price Increase

Doctors and patients say something must be done to stop Catalyst Pharmaceuticals from emulating the high-priced drug strategies of Valeant and Turing Pharma.